Low-Concentration Atropine Composition for Myopia Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing or delaying the onset of myopia and reducing its progression, such as contact lenses and pharmacological agents, are ineffective in addressing myopia before it occurs or in using low-frequency administration of atropine for myopia control.
Innovation Solution
Administering a composition comprising very low concentrations of atropine, specifically less than 0.025%, to the eyes, either daily or less frequently, to prevent or delay the onset of myopia in non-myopic subjects and reduce progression in subjects with existing low myopia, using atropine sulphate and optional excipients like benzalkonium chloride and hydroxypropyl methylcellulose.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods (contact lenses, standard atropine concentrations) are used to prevent or delay myopia onset, then myopia control is attempted, but effectiveness is limited and side effects increase with higher concentrations
Solution Approach 1:
The patent applies parameter changes by using very low concentrations of atropine (0.001%-0.0249%) instead of conventional higher concentrations. This parameter modification allows the composition to effectively delay myopia onset and reduce progression while minimizing harmful side effects such as pupil dilation and accommodation loss, thus resolving the contradiction between effectiveness and side effects
Solution Approach 2:
The patent employs partial action by using sub-conventional doses of atropine that are sufficient to achieve myopia prevention and control goals without causing excessive pharmacological effects. The low concentration regime provides just enough therapeutic effect to delay myopia onset and reduce progression while avoiding the harmful effects associated with higher doses
2Reliability
If high concentration atropine is used to ensure myopia control effectiveness, then prevention capability improves, but side effects such as pupil dilation and accommodation loss increase
Solution Approach 1:
The patent resolves this contradiction by changing the concentration parameter of atropine to very low levels (0.001%-0.0249%). This parameter change maintains the ability to delay myopia onset and reduce progression while significantly reducing the generation of harmful effects like pupil dilation and accommodation loss that occur with higher concentrations
3Reliability
If frequent administration of atropine is performed to maximize prevention effect, then myopia delay effectiveness improves, but treatment complexity and patient burden increase
Solution Approach 1:
The patent applies partial action by demonstrating that low-frequency administration of very low concentration atropine is sufficient to achieve myopia prevention and control. This reduces treatment complexity and patient burden while maintaining effectiveness, as the low concentration requires less frequent dosing to achieve therapeutic benefits
Data Source
AI summary
Methods of preventing or delaying onset of myopia in pre-myopic patients and also methods of reducing or preventing progression of myopia in patients having low myopia through the use of compositions comprising less than 0.025% of atropine are disclosed.